{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:43:14Z","timestamp":1789735394609,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK","award":["209379"],"award-info":[{"award-number":["209379"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is limited information available on the impact of moderate asthma exacerbations, often called \u201casthma attacks\u201d (i.e., those not requiring hospitalisation or treatment with systemic corticosteroids) on patients\u2019 lives. This multi-country qualitative study explored the patient experience of these events.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Semi-structured concept elicitation interviews were conducted in the USA and Germany with adult patients with asthma who had experienced a moderate asthma exacerbation in the prior 30\u00a0days. Physicians with experience in managing patients with asthma were also interviewed. Interviews explored patients\u2019 experience of symptoms and impact of moderate exacerbations and associated exacerbation triggers and treatment patterns. Physicians were also asked about their interpretation of a clinical definition and treatment of a moderate exacerbation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-eight patient (n\u2009=\u200920 in the USA, n\u2009=\u20098 in Germany) and six physician (n\u2009=\u20093 in the USA, n\u2009=\u20093 in Germany) interviews were conducted. During their moderate exacerbation, all patients reported experiencing shortness of breath, which many considered to be severe and the most bothersome symptom. Wheezing was also reported by all patients and considered severe by two thirds of patients. Most patients also reported coughing and chest tightness. All or almost all patients reported that moderate exacerbation caused fatigue\/tiredness and impacted their physical functioning, emotional functioning, activities of daily living and work\/school life. Most patients reported using rescue or maintenance inhalers to alleviate symptoms of the exacerbation. Conceptual saturation (i.e., the point at which no new concepts are likely to emerge with continued data collection) was achieved. Findings were used to develop a patient-focused conceptual model of the experience of moderate asthma exacerbations, outlining concepts related to triggers, symptoms, impact, and treatment from the patient perspective. Physician data was consistent with patient reports and complemented the conceptual model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Findings from concept elicitation interviews highlight the increased frequency, duration and severity of asthma symptoms and increased rescue medication use during moderate asthma exacerbations compared with the typical daily asthma experience, which have a substantial impact on patients\u2019 lives.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-022-00506-2","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T04:36:29Z","timestamp":1669178189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Patient experience of moderate asthma attacks: qualitative research in the USA and Germany"],"prefix":"10.1186","volume":"6","author":[{"given":"Maggie","family":"Tabberer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane R.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Abetz-Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8523-0419","authenticated-orcid":false,"given":"Shiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelmine","family":"Meeraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Slade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"506_CR1","unstructured":"Global Initative for Athma (2020) GINA Report, Global Strategy for Asthma Management and Prevention. Available at: https:\/\/ginasthma.org\/gina-reports\/. Accessed 2 March 2021"},{"issue":"1","key":"506_CR2","doi-asserted-by":"publisher","first-page":"16107","DOI":"10.1038\/s41598-019-52361-9","volume":"9","author":"P Ilmarinen","year":"2019","unstructured":"Ilmarinen P et al (2019) Effect of asthma control on general health-related quality of life in patients diagnosed with adult-onset asthma. Sci Rep 9(1):16107","journal-title":"Sci Rep"},{"issue":"1","key":"506_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3132\/pcrj.2007.00002","volume":"16","author":"A Lloyd","year":"2007","unstructured":"Lloyd A, Price D, Brown R (2007) The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 16(1):22\u201327","journal-title":"Prim Care Respir J"},{"key":"506_CR4","doi-asserted-by":"crossref","unstructured":"Luskin AT, et al (2014) Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract 2(5):544\u2013552 e1\u20132","DOI":"10.1016\/j.jaip.2014.02.011"},{"key":"506_CR5","unstructured":"National Asthma Education Prevention Program (2020) Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. 2007 December 2020]; Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/guidelines-for-diagnosis-management-of-asthma"},{"issue":"6","key":"506_CR6","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jaci.2006.09.006","volume":"118","author":"K McCoy","year":"2006","unstructured":"McCoy K et al (2006) Predicting episodes of poor asthma control in treated patients with asthma. J Allergy Clin Immunol 118(6):1226\u20131233","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"506_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaci.2010.08.042","volume":"127","author":"EO Meltzer","year":"2011","unstructured":"Meltzer EO et al (2011) Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol 127(1):167\u2013172","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"506_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1378\/chest.11-0574","volume":"141","author":"M Schatz","year":"2012","unstructured":"Schatz M et al (2012) The relationship of asthma impairment determined by psychometric tools to future asthma exacerbations. Chest 141(1):66\u201372","journal-title":"Chest"},{"issue":"1","key":"506_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","volume":"180","author":"HK Reddel","year":"2009","unstructured":"Reddel HK et al (2009) An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180(1):59\u201399","journal-title":"Am J Respir Crit Care Med"},{"key":"506_CR10","unstructured":"European Medicines Agency (2015) Guideline on the clinical investigation of medicinal products for the treatment of asthma. Available at: https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-treatment-asthma. Accessed 2 March 2021"},{"issue":"5","key":"506_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.rmed.2015.01.012","volume":"109","author":"JC Virchow","year":"2015","unstructured":"Virchow JC et al (2015) Defining moderate asthma exacerbations in clinical trials based on ATS\/ERS joint statement. Respir Med 109(5):547\u2013556","journal-title":"Respir Med"},{"issue":"8","key":"506_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11136-010-9677-6","volume":"19","author":"KE Lasch","year":"2010","unstructured":"Lasch KE et al (2010) PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res 19(8):1087\u20131096","journal-title":"Qual Life Res"},{"key":"506_CR13","unstructured":"US Food and Drug Administration (2019) Patient-focused drug development: Methods to identify what is important to patients guidance for industry, food and drug administration staff, and other stakeholders. In FDA. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients-guidance-industry-food-and. Accessed 6 January 2022. 2019; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients"},{"issue":"8","key":"506_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL et al (2011) Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument. Value Health 14(8):967\u2013977","journal-title":"Value Health"},{"issue":"10","key":"506_CR15","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ et al (2010) What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health 25(10):1229\u20131245","journal-title":"Psychol Health"},{"issue":"7","key":"506_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM et al (2018) Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health 21(7):839\u2013842","journal-title":"Value Health"},{"key":"506_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12955-015-0217-5","volume":"13","author":"G Globe","year":"2015","unstructured":"Globe G et al (2015) Symptoms and markers of symptom severity in asthma\u2013content validity of the asthma symptom diary. Health Qual Life Outcomes 13:21","journal-title":"Health Qual Life Outcomes"},{"issue":"3 Suppl","key":"506_CR18","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.jaci.2011.12.981","volume":"129","author":"JA Krishnan","year":"2012","unstructured":"Krishnan JA et al (2012) Asthma outcomes: symptoms. J Allergy Clin Immunol 129(3 Suppl):S124\u2013S135","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"506_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jval.2016.01.007","volume":"19","author":"A Gater","year":"2016","unstructured":"Gater A et al (2016) Assessing asthma symptoms in adolescents and adults: qualitative research supporting development of the asthma daily symptom diary. Value Health 19(4):440\u2013450","journal-title":"Value Health"},{"issue":"3","key":"506_CR20","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1183\/09031936.00225014","volume":"46","author":"BD Stucky","year":"2015","unstructured":"Stucky BD et al (2015) Understanding asthma-specific quality of life: moving beyond asthma symptoms and severity. Eur Respir J 46(3):680\u2013687","journal-title":"Eur Respir J"},{"issue":"1","key":"506_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000189","volume":"4","author":"A Crespo-Lessmann","year":"2017","unstructured":"Crespo-Lessmann A et al (2017) Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate-severe asthma. BMJ Open Respir Res 4(1):e000189","journal-title":"BMJ Open Respir Res"},{"issue":"8","key":"506_CR22","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.jaip.2019.04.046","volume":"7","author":"K Matsunaga","year":"2019","unstructured":"Matsunaga K et al (2019) Factors associated with physician-patient discordance in the perception of asthma control. J Allergy Clin Immunol Pract 7(8):2634\u20132641","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"506_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","volume":"9","author":"LA Lee","year":"2021","unstructured":"Lee LA et al (2021) Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med 9(1):69\u201384","journal-title":"Lancet Respir Med"},{"key":"506_CR24","doi-asserted-by":"crossref","unstructured":"Lee L, et al (2020) Characterising asthma exacerbations in the CAPTAIN trial. European Respiratory Society\u201430th Annual Congress","DOI":"10.1183\/13993003.congress-2020.2276"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00506-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-022-00506-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00506-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T04:37:14Z","timestamp":1669178234000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-022-00506-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1186\/s41687-022-00506-2","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"5 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from Copernicus, a centralized Independent Review Board (IRB) based in the USA that provided approval for conduct in the USA and Germany (IRB Protocol # 20200116).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SZ, AF and DS are employees of GSK and hold stock\/shares in GSK. MT and WM were employees of GSK at the time of the study and hold stocks\/shares in GSK. JRW and DC are employed by Adelphi Values, which received funding from GSK for study conduct and data analysis. LA-W is an employee of Patient-Centred Outcomes Assessments Ltd and is an independent consultant to Adelphi Values. No funding was provided to Adelphi Values or Patient-Centred Outcomes Assessments Ltd for manuscript development.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}